ARDELYX, INC.
ARDX evidence brief
What we can confirm
- BioSniper Score:
- 4.7 / 10
- Market Cap:
- $981.1M
- Lead Asset:
- IBSRELA (Approved)
What it means
What to watch
Prepared research question
What matters most for ARDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARDX
ARDELYX, INC. (ARDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing tenapanor-based therapies for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in chronic kidney disease, with two approved products in the U.S. and a growing international presence.
Key risk: Continued net losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst · 2 FDA decisions for ARDELYX, INC..
ARDELYX, INC. (ARDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing tenapanor-based therapies for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in chronic kidney disease, with two approved products in the U.S. and a growing international presence.
- ARDELYX generated net product sales revenue of $377.8 million in 2025 from its two commercial products, IBSRELA and XPHOZAH, representing 18% year-over-year growth [sec · filed 2026-04-29].
- As of 2026-06-30, the company reported cash & equivalents of $97.2M, total revenue of $120.9M, net income of -$16.7M, and shareholders' equity of $149.0M [sec].
- IBSRELA (tenapanor) is approved in the U.S. for adults with IBS-C, and the company believes it can benefit approximately 13 million Americans suffering from IBS-C symptoms [sec_mda · as of 2026-04-30].
- In February 2025, tenapanor was approved in China for controlling serum phosphorus in dialysis patients, triggering a $5.0 million milestone payment from partner Fosun Pharma [sec · filed 2026-04-29].
- The company's pipeline includes Phase 3 studies for a pediatric IBS-C label extension of tenapanor, with trials ongoing for patients aged 6 to less than 18 years old [catalyst].
What works
- ARDELYX has two approved commercial products (IBSRELA and XPHOZAH) generating growing revenue, with 2025 net product sales of $377.8 million, an 18% year-over-year increase [sec · filed 2026-04-29].
- The company has expanded internationally, with tenapanor approved in China and launched under the trade name Wan Ti Le in March 2026, providing a new revenue stream [sec · filed 2026-04-29].
- ARDELYX maintains a solid balance sheet with cash & equivalents of $97.2M as of 2026-06-30 and shareholders' equity of $149.0M, providing financial runway for operations and pipeline development [sec].
What to weigh
- The company remains unprofitable, reporting a net loss of -$16.7M as of 2026-06-30, though executives have stated a target of profitability by 2027 [sec; news · published 2026-09-21].
- XPHOZAH revenue fell short of budget in 2025, with net product revenue of $103.6 million against a budget of $119.1 million, partly due to the loss of Medicare Part D coverage [sec · filed 2026-04-29].
- ARDELYX operates in a highly competitive environment for senior executives and faces competition in its pipeline space, including a Phase 2 competitor from Eli Lilly for IBS-C [sec · filed 2026-04-29; pipeline].
From the filings
Quoted directly from source documents.
2025 net product sales revenue and growth rate
“the Company achieved net product sales revenue of $377.8 million through our two commercial products, IBSRELA ® and XPHOZAH ® , representing 18% year-over-year growth.”
SEC filings · April 29, 2026
China approval and milestone payment
“In February 2025, we announced the approval in China of tenapanor to control serum phosphorus levels in dialysis patients with chronic kidney disease who have an inadequate response or are intolerant to phosphorus binders. Ardelyx received a $5.0 million milestone payment from Fosun Pharma following the approval.”
SEC filings · April 29, 2026
Catalyst timeline
- 2042-11-26 · Patent_Expiry · TENAPANOR HYDROCHLORIDE — Patent_Expiry: NDA213931 — The patent for tenapanor hydrochloride expires, which could allow generic competition for IBSRELA and XPHOZAH.
Risks & what to watch (4)›
Key risks
- Continued net losses — The company reported a net loss of -$16.7M as of 2026-06-30, with profitability not expected until 2027 [sec; news · published 2026-09-21].
- XPHOZAH revenue shortfall — XPHOZAH net revenue of $103.6M in 2025 missed the $119.1M budget, partly due to loss of Medicare Part D coverage [sec · filed 2026-04-29].
- Patent expiry risk — The patent for tenapanor hydrochloride (NDA213931) is set to expire on November 26, 2042, which could eventually open the door to generic competition [catalyst].
- Competitive pipeline pressure — Eli Lilly has a Phase 2 competitor (LY3537031) in the IBS-C space, potentially challenging future label extensions [pipeline].
What to watch
- Revenue trajectory toward the stated $500M target for 2026 and progress toward profitability in 2027 [news · published 2026-09-21].
- Outcomes of ongoing Phase 3 pediatric IBS-C studies for tenapanor, which could expand the addressable market [catalyst].
- Commercial performance of XPHOZAH following the loss of Medicare Part D coverage and any impact on market share [sec · filed 2026-04-29].
- New data presentations at ASN Kidney Week 2026 (October 21–25, 2026) on XPHOZAH real-world evidence and hyperphosphatemia management [news · published 2026-10-05].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run ARDELYX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARDELYX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.86 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~5887d
0 buys · 44 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
236
Total value held
$999.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 21,164,132 | $126.8M |
| millennium management llc | 17,842,370 | $106.9M |
| state street corp | 13,604,307 | $81.5M |
| vanguard capital management llc | 10,365,512 | $62.1M |
| janus henderson group plc | 8,371,234 | $50.1M |
| nomura asset management international inc. | 8,169,369 | $48.9M |
| vanguard portfolio management llc | 6,661,693 | $39.9M |
| geode capital management, llc | 6,007,455 | $36.0M |
| nuveen, llc | 5,234,683 | $31.4M |
| two sigma investments, lp | 4,274,043 | $25.6M |
Showing top 10 of 236 institutional holders of ARDELYX, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 9.8%
- Days to cover
- 7.2
- Shares short
- 23,569,074
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARDELYX, INC.?
ARDELYX, INC. (ARDX) is a commercial-stage biopharmaceutical company focused on developing and commercializing tenapanor-based therapies for irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in chronic kidney disease, with two approved products in the U.S. and a growing international presence.
What is ARDELYX, INC.'s lead drug candidate?
ARDELYX, INC.'s most advanced tracked candidate is IBSRELA (Approved) for Irritable bowel syndrome with constipation (IBS-C) in adults.
What is ARDELYX, INC.'s next catalyst?
ARDELYX, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA213931" — expected November 26, 2042.
Who is the CEO of ARDELYX, INC.?
Mr. Michael G. Raab is the chief executive officer of ARDELYX, INC. (ARDX).
Where is ARDELYX, INC. headquartered?
ARDELYX, INC. (ARDX) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.